Abstract
Identifying risk protein targets and their therapeutic drugs is crucial for effective cancer prevention. Here, we conduct integrative and fine-mapping analyses of large genome-wide association studies data for breast, colorectal, lung, ovarian, pancreatic, and prostate cancers, and characterize 710 lead variants independently associated with cancer risk. Through mapping protein quantitative trait loci (pQTL) for these variants using plasma proteomics data from over 75,000 participants, we identify 365 proteins associated with cancer risk. Subsequent colocalization analysis identifies 101 proteins, including 74 not reported in previous studies. We further characterize 36 potential druggable proteins for cancers or other disease indications. Analyzing >3.5 million electronic health records, we uncover five drugs (Haloperidol, Trazodone, Tranexamic Acid, Haloperidol, and Captopril) associated with increased cancer risk and two drugs (Caffeine and Acetazolamide) linked to reduced colorectal cancer risk. This study offers novel insights into therapeutic drugs targeting risk proteins for cancer prevention and intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the US National Institutes of Health grant 1R37CA227130-01A1 and R01CA269589-01A1 to X.G. The data analyses were conducted using the Advanced Computing Center for Research and Education (ACCRE) at Vanderbilt University. New Frontiers in Research Fund (NFRFE-2018-00748) and NSERC Discovery Grant (RGPIN-2024-04679) to Q.L. The computational infrastructure was partly supported by a Canada Foundation for Innovation JELF grant (36605) to Q.L.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data. The summary statistics of GWAS data for the six common cancers can be accessed through their publications, including Breast cancer(PMID: 32424353), Ovarian cancer(PMID: 28346442), Prostate cancer(PMID: 29892016), Colorectal Cancer(PMID: 30510241), Lung cancer(PMID: 28604730), Pancreatic cancer(PMID: 31917448). Metadata and pQTL summary statistics from UKB-PPP can be downloaded from Synapse: Project SynID: syn51364943; pQTL from ARIC46 and deCODE genetics47 can be accessed through previous publications (PMID: 34857953 and PMID: 35501419). Functional genomic data includes: TCGA and CPTAC differential expression results accessible through https://ualcan.path.uab.edu/index.html; 4DGenome: https://4dgenome.research.chop.edu/; Depmap：https://depmap.org/portal/; FANTOM5: http://fantom.gsc.riken.jp/5/. HaploReg: https://pubs.broadinstitute.org/mammals/haploreg/. GTEx: https://gtexportal.org/home/. GENCODE (v26.GRCh38) was downloaded from https://www.gencodegenes.org/human/release_26.html. National Cancer Institute can be accessed through https://www.cancer.gov/about-cancer/treatment/drugs; CGC can be accessed via COSMIC website: https://cancer.sanger.ac.uk/census. Drugs and compounds data can be downloaded from the following URLs: ChEMBL: https://www.ebi.ac.uk/chembl/; Therapeutic Target Database: https://db.idrblab.net/ttd/; Open Targets: https://www.opentargets.org/; DrugBank: https://go.drugbank.com/. The EHR data, containing de-identified clinical information, can be accessed through the VUMC SD database. Data is available through restricted access for approved studies and researchers who agree to specific conditions of use.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Author names shared co-first authorship
Data availability
Supplementary Table 1 provides the download information for the summary statistics of GWAS data for the six common cancers, including breast, ovary, prostate, colorectum, lung, and pancreas. Metadata and pQTL summary statistics from UKB-PPP can be downloaded from Synapse: Project SynID: syn51364943; pQTL from ARIC46 and deCODE genetics47 can be accessed through previous publications (PMID: 34857953 and PMID: 35501419). Functional genomic data includes: TCGA and CPTAC differential expression results accessible through https://ualcan.path.uab.edu/index.html; 4DGenome: https://4dgenome.research.chop.edu/; Depmap : https://depmap.org/portal/; FANTOM5: http://fantom.gsc.riken.jp/5/. HaploReg: https://pubs.broadinstitute.org/mammals/haploreg/. GTEx: https://gtexportal.org/home/. GENCODE (v26.GRCh38) was downloaded from https://www.gencodegenes.org/human/release_26.html. National Cancer Institute can be accessed through https://www.cancer.gov/about-cancer/treatment/drugs; CGC can be accessed accessed via COSMIC website: https://cancer.sanger.ac.uk/census. Drugs and compounds data can be downloaded from the following URLs: ChEMBL: https://www.ebi.ac.uk/chembl/; Therapeutic Target Database: https://db.idrblab.net/ttd/; Open Targets: https://www.opentargets.org/; DrugBank: https://go.drugbank.com/. The EHR data, containing de-identified clinical information, can be accessed through the VUMC SD database. Data is available through restricted access for approved studies and researchers who agree to specific conditions of use.
